Table 2.

CMML/aCML; JAK2V617F positive cohort


Patient

Sex

Age, y

WBC count, × 109/L

Plt count, × 109/L

Hb, g/L

Karyotype

Splenomegaly

Diagnosis

Progression to AML

Ras mutation

Treatment

Survival, mo
1   F   65   53.9   46   133   Diploid   Yes   CMML   Yes   No   Hydrea, 9NC, oral topotecan   62  
2   M   55   30.4   51   134   Diploid   Yes   CMML   No  NRAS codon 12   Topotecan/Ara-C, Allo-SCT   75+  
3   M   70   48.0   15   63   Diploid   Yes   CMML   No  KRAS codon 13   Daunorubicin, Ara-C, thalidomide   0.2  
4   M   54   37.1   22   108   Diploid   Yes   CMML   No   No   FTI   57  
5   F   71   24.9   272   155   Diploid   No   CMML   No   No   Hydrea   36+  
6   M   74   4.6   177   127   Diploid   No   CMML   No   No   eloposide, skin XRT   27+  
7   M   47   NA   NA   NA   Diploid, trisomy 8 at transformation to AML   Yes   aCML   Yes   No   Hydrea, IFN, Allo-SCT   60+  
8
 
M
 
79
 
6.9
 
99
 
135
 
Diploid
 
Yes
 
CMML
 
Yes
 
No
 
None
 
33+
 

Patient

Sex

Age, y

WBC count, × 109/L

Plt count, × 109/L

Hb, g/L

Karyotype

Splenomegaly

Diagnosis

Progression to AML

Ras mutation

Treatment

Survival, mo
1   F   65   53.9   46   133   Diploid   Yes   CMML   Yes   No   Hydrea, 9NC, oral topotecan   62  
2   M   55   30.4   51   134   Diploid   Yes   CMML   No  NRAS codon 12   Topotecan/Ara-C, Allo-SCT   75+  
3   M   70   48.0   15   63   Diploid   Yes   CMML   No  KRAS codon 13   Daunorubicin, Ara-C, thalidomide   0.2  
4   M   54   37.1   22   108   Diploid   Yes   CMML   No   No   FTI   57  
5   F   71   24.9   272   155   Diploid   No   CMML   No   No   Hydrea   36+  
6   M   74   4.6   177   127   Diploid   No   CMML   No   No   eloposide, skin XRT   27+  
7   M   47   NA   NA   NA   Diploid, trisomy 8 at transformation to AML   Yes   aCML   Yes   No   Hydrea, IFN, Allo-SCT   60+  
8
 
M
 
79
 
6.9
 
99
 
135
 
Diploid
 
Yes
 
CMML
 
Yes
 
No
 
None
 
33+
 

WBC indicates white blood cell; Plt, platelet; Hb, hemoglobin; 9NC, 9-nitrocamptothecin; Ara-C, arabinosyl cytosine; Allo-SCT, allogeneic stem cell transplantation; FTI, farnesyl transferase inhibitors; XRT, radiotherapy; NA, not available; and IFN, interferon.

Close Modal

or Create an Account

Close Modal
Close Modal